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1. Introduction 
Development of tumor resistance to chemotherapeutics is related to inherent tumor 
variations regarding sensitivity to chemotherapeutics and to sub-optimal dosing regimens, 
including variation in patient pharmacokinetics that result in suboptimal exposure of tumor 
cells to anti-neoplastic drugs [1, 2]. The rate and extent of drug efficacy depends on the 
extent of drug exposure at the tumor site and the time above the effective concentration [3]. 
In vitro models that incorporate these pharmacokinetic and pharmacodynamic (PK/PD) 
principles to optimize therapeutic response may be considered the method of choice for 
optimizing dosing schedules before translating data from static assays to animals and 
clinical trials [4, 5]. The hollow fiber bioreactor was recently used to evaluate 
pharmacokinetic/pharmacodynamic (PK/PD) effects of gemcitibine in lung and breast 
cancers and to model HIV treatments [4-6].  
2. Hollow fiber bioreactor model 
The hollow fiber bioreactor model (Figure 1) is a dynamic system that provides a cell culture 
with constant flow of fresh medium through a 3D polysulfone cartridge (support for cell 
growth) with capillary sized passages (cells grow in the extracapillary space), at 
physiologically relevant flow rates. Automatic programmable pumps accurately regulate 
dosing of chemotherapeutics into the system.  
The hollow fiber cartridge consists of two compartments, the porous capillaries through 
which medium flows and the extra-capillary space (ECS) that separates the cell culture from 
the flowing medium. Medium is constantly perfused through the fibers into the ECS, 
carrying nutrients and infused drugs to the cell culture. Due to the dynamic nature of the  
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Fig. 1. Schematic of the bioreactor setup 
model, cells can be exposed to carefully chosen drug concentrations that simulate patient 
pharmacokinetics from published clinical data, simulating drug half-life and renal clearance 
[6]. This change in concentration over time cannot be achieved in static assays. To monitor 
cell growth and viable counts in undisturbed hollow fiber cultures, we used an assay based 
on measurement of fluorescence resulting from the reduction of non-fluorescent resazurin to 
its red fluorescent form (resorufin) by metabolically active cells [7]. The intensity of the 
fluorescence is proportional to the viable cell count [8]. Achievement of cell cycle arrest, as a 
surrogate marker of the therapeutic outcome, was measured by flow cytometry. We 
hypothesized that we could use the proposed dynamic model to accurately simulate (R)-
roscovitine (ROSC) pharmacodynamics, incorporating pharmacokinetic data. To achieve 
this, we used the MCF-7 human breast cancer cell line and compared the peak values from 
two proposed dosing regimens of ROSC to untreated controls.  
MCF-7 cells are derived from the pleural effusion of an estrogen receptor positive, human 
breast adenocarcinoma [9, 10]. Cells were cultured in EMEM, 2mM L-glutamine, 0.1mM 
non-essential amino acids, 1mM sodium pyruvate, 0.01mg/mL bovine insulin and 10% fetal 
bovine serum; grown in 5% CO2 at 37o C and dispersed when confluent with of 0.25% 
trypsin/0.5mM EDTA. Hollow fiber cartridges were prepared according to manufacturers 
instructions. To prepare hollow fiber cultures, briefly, trypsinized cells were diluted to 1.67 
x 106/mL; 3mL were seeded into the ECS of each cartridge. Two cartridges were seeded for 
each experiment; one for drug treatment and one control. Cartridges were placed on a dual 
recirculating pump in the incubator at 37°C with 5% CO2 to circulate fresh sterile medium to 
each cartridge simultaneously while establishing the cultures.  
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2.1 Pharmacokinetic simulation for (R)-roscovitine 
After 24 hours, cartridges were removed from the recirculating pump, connected to a linear 
pump system (Masterflex) and a digital syringe pump was used to control the rate of drug 
infusion (Figure 1). Mathematical pharmacokinetic drug profiles were simulated by 
adjusting the input of ROSC and medium in the system. Infusion of the drug at peak 
concentration was followed by simulation of its clearance rate over a 6 hour period. Controls 
were perfused with drug free medium under the same conditions. Each dosing schedule 
was performed at least in duplicate.  
2.2 PK/PD simulation for the bioreactor 
A one compartment model, oral absorption and first order elimination was constructed 
using STELLA software (isee systems inc., Lebanon, NH). This model simulated 
pharmacokinetic profiles of peak and trough plasma levels after 800 mg twice daily (BID) 
and three times daily (TID) dosage regimens using pharmacokinetic parameters from a 
previously published clinical trial [11]. STELLA simulation provided a profile range of 
several Cmax from which to mimic the Css (steady state concentration) in the bioreactor. To 
accomplish this infusion, peak and trough concentrations of the Css range were used to 
determine the final dose, which represented the population pharmacokinetics and was 
infused to the central reservoir. Simulated BID peak and trough concentrations were 3167 
ng/mL and 808 ng/mL, respectively. Simulated TID peak and trough concentrations were 
3893 ng/mL and 1923 ng/mL, respectively. Flow rates for the pumps were determined 
using the following equation for oral administration: 
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where Cl is clearance of drug and is equal to the rate set on the Masterflex pumps, ke is the 
elimination rate constant for ROSC, Vd is central reservoir volume, C1 is Cmax from the 
simulation during the steady state, C2 is Cmin from the simulation during the steady state, 
and t (time) is the experiment duration. The rate of the digital pumps simulated the patient 
drug clearance.  
2.3 LC/MS 
To confirm the achievement of peak drug concentrations, samples were collected from the 
ECS of the hollow fiber cartridge and analyzed by LC/MS. The system included two 
Shimadzu LC- 20AD pumps, SIL-20AC autosampler, 2010 EV mass spectrometer with 
cosense module. A BDS Hypersil C18 (30mm x 2.1mm x 3µm) analytical column was used in 
conjunction with the co-sense system fitted with a Shimadzu MAYI-ODS 10L x 4.6 column. 
Mobile phase; A ( 10% ACN/ 90%, 0.1% Formic Acid) v/v and B (80% ACN and 20%, 0.1% 
Formic Acid) v/v; gradient at 50 % B increasing to 100% B over 1 min and remained 
isocratic at 100% B for 6 minutes until returning to 50% B. Flow rate was 0.150 ml/min with 
detection wavelength of 292 nm with an injection volume of 10μL. Mass spectrometry peaks 
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were analyzed using Shimadzu’s data analysis program. Peak integrations were compared 
to a standard curve to obtain the concentrations of ROSC. 
2.4 Resazurin assay 
Fluorescent conversion of resazurin is directly related to the number of metabolically active 
cells in culture and serves as a surrogate probe for viable cell count. Medium containing 5% 
v/v resazurin was added to the hollow fiber system and circulated for 30 minutes for 
homogenous distribution of resazurin containing medium. System valves were closed and 
the cartridge incubated 2 hours; 200 µl samples were drawn from medium in the ECS. 
Fluorescence was measured on a microplate reader (Biotek, Winooski, VT). Resazurin was 
removed by pumping fresh medium through the system with linear pumps, collecting the 
resazurin medium as waste. Assays were performed before and after treatment for assessing 
baseline fluorescence and the effect of drug on cell proliferation. Resazurin has been 
reported to be cytotoxic at high concentrations and exposure beyond 24 hours [12]. Since cell 
lines respond differently to resazurin, [13], we conducted a static assay to establish that 5% 
(v/v) resazurin could be used over at least a 24 hour period without toxicity to the MCF-7 
cell line. Cells incubated with resazurin, and untreated controls, were harvested, stained 
with trypan blue and counted at the conclusion of the experiment. This confirmed that 
growth and viability were unaffected by resazurin at 5% v/v (unpublished data).  
2.5 Flow cytometry 
MCF-7 cells were harvested from the hollow fiber cartridge by trypsinization and 
centrifuged at 300x g for 5 minutes. Supernatant was removed and the pellet resuspended in 
0.5ml of PBS-T with 20 µg/mL of RNAse and incubated at 37°C for 30 min. 10μg/ml 
propidium iodide was added to the cell suspension and incubated at 37°C for 30 min. The 
stained nuclei (200,000 per sample) were analyzed with a Becton Dickinson FACSCalibur 
(San Jose, California) flow cytometer using medium flow mode. Cell cycle distribution was 
analyzed with Modfit LT program (Verity, Maine). 
3. Results 
Pharmacokinetic simulation of ROSC was used to predict the Cmax of BID and TID dosing 
regimens. The predicted bolus dose values for the BID and TID were 3167ng/mL (8.9µM) 
and 3893ng/mL (10.9µM), respectively. From this data, we modeled a one dose peak profile 
that we could assess in the in vitro hollow fiber model. Actual concentrations of ROSC 
achieved in the model reached a Cmax of 2953 ng/mL (8.3µM) for the BID schedule, an 
accuracy of 93.2% compared to the predicted value. Actual concentration for the TID 
schedule was 3307ng/mL (9.3µM) as compared to the mathematical profile Cmax of 
3893ng/mL, an accuracy of 85.0%. This level of accuracy for infused drug is consistent with 
the reports of Kirstein, et al. in their PK/PD studies in the hollow fiber model [5, 6]. To 
monitor cell proliferation and viability before treatment, without disturbing established 
cultures, we used the resazurin assay on all cartridges. There was no significant difference in 
cell proliferation between cartridges before treatment (p=0.86), indicating consistency in 
seeding the hollow-fiber cartridges. In post-treatment resazurin assays, ROSC treated 
cartridges had decreased cell proliferation compared to control cartridges. The TID (9.3µM) 
simulated dose had a 15-20% decrease in growth that was not evident with the BID (8.3 µM) 
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simulated dose (Figure 2). To determine the effect of ROSC on cell cycle, cells were collected 
by trypsinization from the hollow-fiber cartridge at 24 hours post-treatment and analyzed 
by flow cytometry. An increase was seen in the proportion of cells in the G1 phase in both 
the BID and TID treatments compared to the control. Correspondingly, there was a 
statistically significant decrease of the proportion of S phase cells in both the TID (p=0.004) 
and BID (p=0.003) doses compared to the control and a statistically significant increase in G2 
for BID simulation (Table 1).  
 
Effect of roscovitine on cell proliferation in the hollow fiber 
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Fig. 2. Evaluation of cell proliferation in undisturbed cultures in the hollow fiber cartridge. 
Samples were taken for each set of cartridges for each experiment (n=2). A sample was 
taken from each cartridge before treatment (n=6). ROSC was infused at steady state value 
and clearance rate was simulated over 6 hours. Sample was taken at 24 hours (18 hours after 
infusion). Fluorescence was quantified as RFU and all values were normalized to the 
untreated control (final average value as 100%).  
 
  G1 (%) S (%) G2 (%) 
Control (n=5) 48.75 ± 3.71 33.93 ± 6.36 17.23 ± 2.68 
BID (n=6) 54.51 ± 3.69 23.15 ± 1.89 22.34 ± 1.86 
TID (n=5) 59.77 ± 3.86 22.49 ± 1.86 17.72 ± 5.55 
n= number of experimental repetitions; BID 800mg twice daily; TID 800mg three times daily. 
Table 1. Effect of ROSC dose increase on cell cycle distribution.  
MCF-7 cells in each measured phase of growth cycle (G1, S or G2) are expressed as a 
percentage (+ Standard Deviation) of the total number of cells.  
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4. Discussion 
Uncontrolled proliferation is a defining characteristic of tumor cells. This is known to occur 
through mutation in genes that produce regulatory proteins which modulate cell cycle, such 
as the Cyclin Dependent Kinases (Cdks) [14-16]. Cdks are highly conserved 
serine/threonine kinases whose activation depends on formation of a heterodimeric 
complex with cyclins [17-19]. Thus, Cdks are a promising therapeutic target for cancer 
treatment [20]. ROSC is a novel Cdk inhibitor that induces cell cycle arrest and apoptosis 
through multiple intracellular targets in a variety of tumor cell lines. When tested in static in 
vitro assays, IC50 values of about 14µM are reported with 24 hours of drug exposure [21-24]. 
However, dosing schedules of 2500 mg/day over 5 days in 3 week cycles or the reduced 
dose of 1600mg/day BID for 10 days were recommended based on early human trials [25] 
and a concomitant Phase one trial that indicated a dose limiting toxicity of 800 mg BID for 7 
days. With this dosing schedule, peak plasma levels were achieved in 1-4 hours with 
elimination by 2-5 hours. The highest plasma concentration achieved clinically was 10µM 
within a treatment period. There was no tumor response to this dose, although the disease 
was stabilized over several courses of treatment [11]. To investigate the effect of 
administration of ROSC as a monotherapy by altering the dosing schedule, we employed a 
dynamic hollow fiber model in this study. We established our model using STELLA to 
simulate pharmacokinetic profiles of ROSC derived from clinical data. These profiles were 
simulated in the in vitro hollow fiber model for assessing the effectiveness of two dosing 
regimens against MCF-7 cells by using flow cytometry to measure cell cycle distribution 
under each condition. The results revealed increasing numbers of MCF-7 cells accumulating 
in G1 phase after simulating the BID and TID dosing peaks with ROSC, and indicating a 
significant difference between TID and the control. Also, BID dosing simulation had a 
significant increase in G2 arrest (p<0.05). This data is consistent with previous studies which 
indicated arrest of MCF-7 cell proliferation at the G1/S transition and G2/M transition with 
accumulation in G2. However, Wesierska-Gadek, et al. revealed ROSC activity only at the 
G2/M transition and accumulation of arrested MCF-7 cells only in the G2 phase. The 
differences may be attributed to differences in their experimental design, as they exposed 
MCF-7 cells in a static system to 10µM ROSC for 24 hours [26]. In this study, we tested 
concentrations of ROSC based on human clinical trial values of a maximum value of 10µM 
over 1-4 hours, with ROSC clearance within 5 hours, which were below the levels tested in 
static systems [11]. In this case, dose limiting toxicity of the drug precludes achievement of 
effective plasma concentrations in humans, which is consistent with the clinical trials. 
Consequently, ROSC is now being tested in combination therapies [27]. In conclusion, this 
study demonstrated the application of the dynamic hollow fiber model with controlled 
pharmacokinetic profiles to simulate clinically relevant dosing schedules of ROSC for 
treatment of breast tumor cells and the use of a resazurin assay for monitoring cell viability 
of hollow fiber cell cultures. With this methodology, cells can be recovered for further 
analysis. The applied hollow fiber model in this study can be used for PK/PD assessment of 
different anti-neoplastic drugs (single and in combination), with different exposure times 
against many tumor cell lines.  
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